|Articles|April 1, 1999

April 1999
Volume 5
Issue 4

Disease Management of Congestive Heart Failure

Author(s)David J. Whellan, MD, Wendy A. Gattis, PharmD, Laura Gaulden, NP

Download PDF: Disease Management of Congestive Heart Failure

Articles in this issue

almost 27 years ago

Article

Medicaid Recipients' Experiences Under Mandatory Managed Care

almost 27 years ago

Article

Why Primary Care Physicians Join HMOs

almost 27 years ago

Article

Discontinuation Rates of Cholesterol-Lowering Medications

almost 27 years ago

Article

The Role of Resource Allocation Models in Selecting Clinical Preventive Services

almost 27 years ago

Article

Is Prior Authorization of Topical Tretinoin for Acne Cost Effective?

almost 27 years ago

Article

Impact of Therapeutic Interchange from Pravastatin to Lovastatin in a Veterans Affairs Medical Center

almost 27 years ago

Article

Targeted Intervention Programs: Creating a Customized Practice Model to Improve the Treatment of Allergic Rhinitis in a Managed Care Population

almost 27 years ago

Article

Celecoxib: A COX-2 Inhibitor

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

Disease Management of Congestive Heart Failure

Articles in this issue

Newsletter

Related Content

Quality of Life: The Pending Outcome in Idiopathic Pulmonary Fibrosis

Increased Payments to Medicare Advantage Plans for Dually Eligible Beneficiaries

The Health Information Technology Special Issue: Tracking Expansion Across Settings, Technologies, and Stakeholders

Building Trust: Public Priorities for Health Care AI Labeling

Ambient AI Tool Adoption in US Hospitals and Associated Factors

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

How Do GLP-1 Agonists Fit Into Stroke Care?

Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making

Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD

5 Things to Know About the Oral GLP-1 Era